Eisai US
Research-driven biopharmaceutical company focused on neurology and oncology. Emphasizes translational research and biomarker and imaging development for earlier diagnosis, conducts and sponsors multi-phase clinical trials, develops biologics and targeted cancer therapeutics (including monoclonal antibodies, antibody-drug conjugates and targeted protein degradation), applies disease-simulation and pharmacometric modeling for outcomes and dosing support, operates U.S.-based manufacturing and patient-support activities, and conducts corporate advocacy, community outreach and virtual medical-affairs engagement.
Industries
Nr. of Employees
Very Large (1000+)
Products
Clinical-stage monoclonal antibody therapeutic for early Alzheimer’s disease
Humanized monoclonal antibody therapeutic developed to bind and reduce pathological amyloid species with the objective of slowing progression in early-stage Alzheimer’s disease; evaluated in multi-phase clinical trials and regulatory submissions.
Clinical-stage monoclonal antibody therapeutic for early Alzheimer’s disease
Humanized monoclonal antibody therapeutic developed to bind and reduce pathological amyloid species with the objective of slowing progression in early-stage Alzheimer’s disease; evaluated in multi-phase clinical trials and regulatory submissions.
Services
Design and conduct of clinical trials across phases for neurology and oncology indications; partnerships with academic consortia and industry collaborators.
Collaborative development and validation of blood-based and fluid biomarker assays to support early disease detection, patient selection and monitoring.
Omnichannel HCP engagement including virtual webcasts, field medical support, digital opinion-leader programs and educational content dissemination.
Programs and community partnerships to support patient needs, improve trial access and inform patient-centered research; includes employee-led volunteer efforts and partnerships with local organizations (e.g., veteran support and therapeutic programs).
Design and conduct of clinical trials across phases for neurology and oncology indications; partnerships with academic consortia and industry collaborators.
Collaborative development and validation of blood-based and fluid biomarker assays to support early disease detection, patient selection and monitoring.
Omnichannel HCP engagement including virtual webcasts, field medical support, digital opinion-leader programs and educational content dissemination.
Programs and community partnerships to support patient needs, improve trial access and inform patient-centered research; includes employee-led volunteer efforts and partnerships with local organizations (e.g., veteran support and therapeutic programs).
Expertise Areas
- Neurology drug development
- Alzheimer’s disease biomarker discovery and validation
- Clinical trial management (Phase 1–3)
- Oncology drug discovery and targeted therapeutics
Key Technologies
- Monoclonal antibody therapeutics
- Antibody-drug conjugates
- Targeted protein degradation modalities (molecular glue/PROTAC-like)
- Blood-based biomarker assays
News & Updates
First-person account describing diagnosis, treatment and the role of screening and early detection; includes reflections on patient experience and corporate advocacy.
Overview of efforts to advance blood-based biomarker assays and partnerships to enable earlier detection and monitoring of Alzheimer’s disease.
Publication of simulation-modeling results estimating potential clinical and socioeconomic value and value-based pricing scenarios using a disease-simulation framework.
Description of community partnership and volunteer activities supporting veterans through equine-assisted therapy and local nonprofit collaboration.
Discussion of adapting field medical and MSL activities to virtual engagement, telemedicine-style interactions and remote scientific exchange.
Recognition for innovation in medicines and therapeutics and for integrating patient-centered approaches into R&D.
First-person account describing diagnosis, treatment and the role of screening and early detection; includes reflections on patient experience and corporate advocacy.
Overview of efforts to advance blood-based biomarker assays and partnerships to enable earlier detection and monitoring of Alzheimer’s disease.
Publication of simulation-modeling results estimating potential clinical and socioeconomic value and value-based pricing scenarios using a disease-simulation framework.
Description of community partnership and volunteer activities supporting veterans through equine-assisted therapy and local nonprofit collaboration.
Discussion of adapting field medical and MSL activities to virtual engagement, telemedicine-style interactions and remote scientific exchange.
Recognition for innovation in medicines and therapeutics and for integrating patient-centered approaches into R&D.